Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000807219 | SCV000947262 | pathogenic | Glucose-6-phosphate transport defect | 2018-10-16 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in SLC37A4 are known to be pathogenic (PMID: 9758626, 10940311). This variant has not been reported in the literature in individuals with SLC37A4-related disease. This variant is present in population databases (rs782172072, ExAC 0.009%). This sequence change creates a premature translational stop signal (p.Val313Serfs*13) in the SLC37A4 gene. It is expected to result in an absent or disrupted protein product. |
Centogene AG - |
RCV000807219 | SCV001424492 | pathogenic | Glucose-6-phosphate transport defect | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000807219 | SCV004222672 | pathogenic | Glucose-6-phosphate transport defect | 2023-11-15 | criteria provided, single submitter | clinical testing | Variant summary: SLC37A4 c.936dupA (p.Val313SerfsX13) results in a premature termination codon, predicted to cause absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant allele was found at a frequency of 8.3e-06 in 241170 control chromosomes. c.936dupA has been reported in the literature in individuals affected with Glycogen Storage Disease Type Ib (example, Veiga_1998, Halligan_1998). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 33977030, 9758626). One submitter has cited clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |